These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26526078)

  • 1. Cell-free DNA as a prognostic marker in stage I non-small-cell lung cancer patients undergoing stereotactic body radiotherapy.
    Bortolin MT; Tedeschi R; Bidoli E; Furlan C; Basaglia G; Minatel E; Gobitti C; Franchin G; Trovò M; De Paoli P
    Biomarkers; 2015; 20(6-7):422-8. PubMed ID: 26526078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.
    Dowler Nygaard A; Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Oncol Rep; 2014 Feb; 31(2):969-74. PubMed ID: 24316734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
    Ai B; Liu H; Huang Y; Peng P
    Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.
    Sirera R; Bremnes RM; Cabrera A; Jantus-Lewintre E; Sanmartín E; Blasco A; Del Pozo N; Rosell R; Guijarro R; Galbis J; Sánchez JJ; Camps C
    J Thorac Oncol; 2011 Feb; 6(2):286-90. PubMed ID: 21252717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic body radiation therapy and intensity modulated radiation therapy induce different plasmatic cytokine changes in non-small cell lung cancer patients: a pilot study.
    Trovo M; Giaj-Levra N; Furlan C; Bortolin MT; Muraro E; Polesel J; Minatel E; Tedeschi R; Filippi AR; Alongi F; Ricardi U
    Clin Transl Oncol; 2016 Oct; 18(10):1003-10. PubMed ID: 26687367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules.
    Szpechcinski A; Rudzinski P; Kupis W; Langfort R; Orlowski T; Chorostowska-Wynimko J
    Cancer Lett; 2016 May; 374(2):202-7. PubMed ID: 26854716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma cfDNA as a potential treatment monitoring and prognostic index in patients withnon-small cell lung cancer.
    Chen N; Li G; Li H; Xiang X; Guo G; Ma Q; Zhang Y
    Cell Mol Biol (Noisy-le-grand); 2020 Jul; 66(5):208-213. PubMed ID: 33040838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis.
    Leng S; Zheng J; Jin Y; Zhang H; Zhu Y; Wu J; Xu Y; Zhang P
    Clin Chim Acta; 2018 Feb; 477():160-165. PubMed ID: 29113814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers.
    Li BT; Drilon A; Johnson ML; Hsu M; Sima CS; McGinn C; Sugita H; Kris MG; Azzoli CG
    Ann Oncol; 2016 Jan; 27(1):154-9. PubMed ID: 26487589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
    Vinayanuwattikun C; Sriuranpong V; Tanasanvimon S; Chantranuwat P; Mutirangura A
    J Thorac Oncol; 2011 Nov; 6(11):1818-25. PubMed ID: 21964525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.
    Haidar YM; Rahn DA; Nath S; Song W; Bazhenova L; Makani S; Fuster MM; Sandhu AP
    Ther Adv Respir Dis; 2014 Feb; 8(1):3-12. PubMed ID: 24334338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing.
    He Y; Zhang X; Wang L; Tian Z; Liu Q; Yao J; Liu Y; Li C; Min L; Shan B
    Int J Oncol; 2016 Dec; 49(6):2351-2358. PubMed ID: 27748796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
    Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R;
    JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients.
    Winther-Larsen A; Demuth C; Fledelius J; Madsen AT; Hjorthaug K; Meldgaard P; Sorensen BS
    Br J Cancer; 2017 Aug; 117(5):704-709. PubMed ID: 28683468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma.
    Mazurek AM; Fiszer-Kierzkowska A; Rutkowski T; Składowski K; Pierzyna M; Scieglińska D; Woźniak G; Głowacki G; Kawczyński R; Małusecka E
    Cancer Biomark; 2013; 13(5):385-94. PubMed ID: 24440979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer.
    Henderson M; McGarry R; Yiannoutsos C; Fakiris A; Hoopes D; Williams M; Timmerman R
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):404-9. PubMed ID: 18394819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates.
    Jeppesen SS; Schytte T; Jensen HR; Brink C; Hansen O
    Acta Oncol; 2013 Oct; 52(7):1552-8. PubMed ID: 23902274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer.
    Tissot C; Toffart AC; Villar S; Souquet PJ; Merle P; Moro-Sibilot D; Pérol M; Zavadil J; Brambilla C; Olivier M; Couraud S
    Eur Respir J; 2015 Dec; 46(6):1773-80. PubMed ID: 26493785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.